In many cases, chronic inflammatory dermatoses are accompanied by changes of the nails or periungual region. Sometimes nail changes occur even before the onset of the particular skin disease. In some cases, specific lesions of the nails and the perionychium can contribute to the diagnosis. This review describes the most common nail and periungual changes in chronic inflammatory dermatoses and the corresponding treatment options. Among others, this review deals with nail changes in collagenoses, autoimmune bullous dermatoses, alopecia areata, lichen planus and atopic eczema. Nail psoriasis is not discussed here, as this special edition contains a review devoted entirely to the complex topic of nail psoriasis.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s00105-025-05489-x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Fc-mediated immune stimulating, pro-inflammatory and antitumor effects of anti-HER2 IgE against HER2-expressing and trastuzumab-resistant tumors.
J Immunother Cancer
March 2025
St. John's Institute of Dermatology, School of Basic & Medical Biosciences & KHP Centre for Translational Medicine, King's College London, London, UK
Background: Anti-human epidermal growth factor receptor 2 (HER2) IgG1-based antibody therapies significantly improve cancer prognosis, yet intrinsic or acquired resistance to fragment antigen-binding (Fab)-mediated direct effects commonly occurs. Most resistant tumors retain antigen expression and therefore remain potentially targetable with anti-HER2 therapies that promote immune-mediated responses. Tumor-antigen-specific IgE class antibodies can mediate powerful immune cell-mediated effects against different cancers and have been shown to activate IgE Fc receptor-expressing monocytes.
View Article and Find Full Text PDFThe novel lysophosphatidic acid receptor 1-selective antagonist, ACT-1016-0707, has unique binding properties that translate into effective antifibrotic and anti-inflammatory activity in different models of pulmonary fibrosis.
J Pharmacol Exp Ther
February 2025
Idorsia Pharmaceuticals Ltd, Allschwil, Switzerland.
Pulmonary fibrosis encompasses different chronic interstitial lung diseases, and the predominant form, idiopathic pulmonary fibrosis, remains to have a poor prognosis despite 2 approved therapies. Although the exact pathobiological mechanisms are still incompletely understood, epithelial injury and aberrant wound healing responses contribute to the gradual change in lung architecture and functional impairment. Lysophosphatidic acid (LPA)-induced lysophosphatidic receptor 1 (LPA1) signaling was proposed to be a driver of lung fibrosis, and LPA1 antagonists have shown promising antifibrotic profiles in early clinical development.
View Article and Find Full Text PDFTargeting IL-23 in Psoriatic Arthritis: A Review of Guselkumab's Efficacy and Utilization.
Skin Therapy Lett
March 2025
Center for Clinical Studies, Webster, TX, USA.
Psoriatic arthritis (PsA) is a chronic, inflammatory disease with heterogeneous clinical features. The pathogenesis of PsA involves a complex interplay of genetic, immunologic, and environmental factors, leading to the activation of the immune system and subsequent inflammation. Over the past decade, the understanding of the immune mechanisms underlying PsA has advanced significantly, particularly regarding the role of the interleukin-23/T helper 17 pathway in the disease process.
View Article and Find Full Text PDFRoflumilast for the Treatment of Seborrheic Dermatitis: A Review.
Skin Therapy Lett
March 2025
University of Central Florida/HCA Healthcare Consortium, Tallahassee, FL, USA.
Seborrheic dermatitis (SD) is a chronic inflammatory skin disorder most commonly affecting areas rich in sebaceous glands, such as the scalp, face, axilla, and groin. Several factors can precipitate SD development, such as colonization of Malassezia, sebocyte activity, impaired immunity, and environmental influences. Topical antifungals, corticosteroids, and calcineurin inhibitors are the current mainstay treatment of SD.
View Article and Find Full Text PDFVancomycin- induced leukocytoclastic vasculitis in a patient with end-stage renal disease: a case report and literature review.
Daru
March 2025
Thoracic Research Center, Imam Khomeini, Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran.
Introduction: Leukocytoclastic vasculitis (LCV) is a small-vessel inflammatory condition that can rarely occur as an adverse drug reaction (ADR). Vancomycin-induced LCV is an uncommon but potentially serious complication, particularly in patients with pre-existing renal impairment.
Reason For The Report: This case report describes a patient with end-stage renal disease (ESRD) who developed LCV following vancomycin therapy for a catheter-related infection.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!